Maclachlan T - Search Results

1

The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases.

Brooks PJ, Miller TM, Revah F, Suh J, Garrison BR, Starke LC, MacLachlan TK, Neilan EG, Raychaudhuri G, Kassim SH, Dehdashti J, Rutter JL. Brooks PJ, et al. Among authors: maclachlan tk. Nat Rev Drug Discov. 2024 Mar;23(3):157-158. doi: 10.1038/d41573-024-00020-8. Nat Rev Drug Discov. 2024. PMID: 38321319 No abstract available.

2

Species-Specific Responses to Human Trampling Indicate Alpine Plant Size Is More Sensitive than Reproduction to Disturbance.

Chardon NI, Stone P, Hilbert C, Maclachlan T, Ragsdale B, Zhao A, Goodwin K, Collins CG, Hewitt N, Elphinstone C. Chardon NI, et al. Among authors: maclachlan t. Plants (Basel). 2023 Aug 24;12(17):3040. doi: 10.3390/plants12173040. Plants (Basel). 2023. PMID: 37687287 Free PMC article.

3

CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.

Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, Lewandowski A, Zhao X, Chitnis S, Peddinti R, Zheng Y, Kapoor N, Ciceri F, Maclachlan T, Yang Y, Liu Y, Yuan J, Naumann U, Yu VWC, Stevenson SC, De Vita S, LaBelle JL. Sharma A, et al. Among authors: maclachlan t. N Engl J Med. 2023 Aug 31;389(9):820-832. doi: 10.1056/NEJMoa2215643. N Engl J Med. 2023. PMID: 37646679 Clinical Trial.

4

Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies.

Moffit JS, Blanset DL, Lynch JL, MacLachlan TK, Meyer KE, Ponce R, Whiteley LO. Moffit JS, et al. Among authors: maclachlan tk. Hum Gene Ther. 2022 Nov;33(21-22):1126-1141. doi: 10.1089/hum.2022.090. Epub 2022 Sep 14. Hum Gene Ther. 2022. PMID: 35994386 Free PMC article.

5

Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019.

MacLachlan TK, Price S, Cavagnaro J, Andrews L, Blanset D, Cosenza ME, Dempster M, Galbreath E, Giusti AM, Heinz-Taheny KM, Fleurance R, Sutter E, Leach MW. MacLachlan TK, et al. Regul Toxicol Pharmacol. 2021 Apr;121:104872. doi: 10.1016/j.yrtph.2021.104872. Epub 2021 Jan 22. Regul Toxicol Pharmacol. 2021. PMID: 33485926

6

Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.

MacLachlan TK, Kronenberg S, Marshall N, Andrews L, Berens SJ, Brouta F, Fogal B, Freebern W, Herzyk D, Kamperschroer C, Kiessling A, Schneidkraut M, Maier C. MacLachlan TK, et al. Regul Toxicol Pharmacol. 2021 Feb;119:104825. doi: 10.1016/j.yrtph.2020.104825. Epub 2020 Nov 19. Regul Toxicol Pharmacol. 2021. PMID: 33220389

7

Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective.

Bolt MW, Whiteley LO, Lynch JL, Lauritzen B, Fernández de Henestrosa AR, MacLachlan T, Ulrich P, Philip BK, Mahalingaiah PK, Fuller CL, Compton DR. Bolt MW, et al. Among authors: maclachlan t. Mol Ther Methods Clin Dev. 2020 Sep 1;19:89-98. doi: 10.1016/j.omtm.2020.08.017. eCollection 2020 Dec 11. Mol Ther Methods Clin Dev. 2020. PMID: 33024793 Free PMC article.

8

Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.

Sato Y, Bando H, Di Piazza M, Gowing G, Herberts C, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW. Sato Y, et al. Among authors: maclachlan t. Cytotherapy. 2019 Nov;21(11):1095-1111. doi: 10.1016/j.jcyt.2019.10.001. Epub 2019 Nov 9. Cytotherapy. 2019. PMID: 31711733 Free article. Review.

9

Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.

Brennan FR, Andrews L, Arulanandam AR, Blumel J, Fikes J, Grimaldi C, Lansita J, Loberg LI, MacLachlan T, Milton M, Parker S, Tibbitts J, Wolf J, Allamneni KP. Brennan FR, et al. Among authors: maclachlan t. Regul Toxicol Pharmacol. 2018 Oct;98:98-107. doi: 10.1016/j.yrtph.2018.07.009. Epub 2018 Jul 17. Regul Toxicol Pharmacol. 2018. PMID: 30026135

10

Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa.

MacLachlan TK, Milton MN, Turner O, Tukov F, Choi VW, Penraat J, Delmotte MH, Michaut L, Jaffee BD, Bigelow CE. MacLachlan TK, et al. Mol Ther Methods Clin Dev. 2017 Dec 22;8:105-120. doi: 10.1016/j.omtm.2017.12.001. eCollection 2018 Mar 16. Mol Ther Methods Clin Dev. 2017. PMID: 29359172 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page